Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Sipuleucel-T is an autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
• Potential racial differences in immune responses to sipuleucel-T require investigation.

Purpose of the Study:

• To explore racial differences in immune responses to sipuleucel-T in men with mCRPC.
• To compare immune correlates between African American (AA) and non-African American (non-AA) patients.

Main Methods:

• Single-arm, two-cohort, multicenter clinical study.
• Assessment of serum cytokines, humoral, and cellular immunity markers pre- and post-treatment.
• Quantification of IgM titers, T-cell activity (ELISpots), and cytokine/chemokine concentrations.

Main Results:

• Non-AA men had higher baseline product parameters; AA men had higher baseline PSA.
• No racial differences in IgM antibody and IFNγ ELISpots responses.
• AA men showed significantly higher ICOS expression on T cells and specific cytokine/chemokine levels.

Conclusions:

• Immune correlates in blood differ between AA and non-AA men with mCRPC pre- and post-sipuleucel-T.
• Higher ICOS expression in AA men suggests distinct T-cell activation patterns.
• Further investigation into immune system differences in AA men with mCRPC is warranted.